CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares rose 0.2% on Tuesday . The stock traded as high as $2.07 and last traded at $2.01. Approximately 6,834 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 9,924 shares. The stock had previously closed at $2.00.
CytoMed Therapeutics Stock Up 0.2%
The company has a debt-to-equity ratio of 0.05, a current ratio of 9.89 and a quick ratio of 9.89. The firm’s 50-day simple moving average is $1.98 and its two-hundred day simple moving average is $2.25.
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Recommended Stories
- Five stocks we like better than CytoMed Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Amazon Faces Rare Downgrade—Is the Rally at Risk?
- High Flyers: 3 Natural Gas Stocks for March 2022
- CrowdStrike Tests $412 Support as Options Traders Turn Bullish
- Why Are These Companies Considered Blue Chips?
- Dueling Insider Moves: Heavy Buying Here, Big Selling There
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
